TC-5214

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HypertensionMajor Depressive Disorder

566 competitors in Hypertension

#DrugCompanyPhaseTrials

1

TC-5214

AstraZeneca

Phase 3

22

Edarbi

Takeda

Preclinical

103

Benicar

Novartis

Preclinical

74

Zebeta

Teva

Preclinical

65

Aceon

Institut de Recherches Internationales Servier

Preclinical

56

Winrevair

Merck & Co.

Preclinical

—7

Alphagan

AbbVie

Preclinical

—8

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

19

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

—10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder6 trials

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Terminated·AstraZeneca·Phase 2·NCT01288079·145 enrolled

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Completed·AstraZeneca·Phase 3·NCT01153347·2,409 enrolled

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Completed·AstraZeneca·Phase 3·NCT01157078·319 enrolled

Show 3 more trials

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Completed·AstraZeneca·Phase 3·NCT01152554·813 enrolled

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Completed·AstraZeneca·Phase 3·NCT01180400·295 enrolled

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Completed·AstraZeneca·Phase 3·NCT01197508·696 enrolled

Hypertension2 trials

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Terminated·AstraZeneca·Phase 1·NCT01403922·80 enrolled

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

Terminated·TTargacept Inc.·Phase 1/2·NCT00899977·1 enrolled

Tics2 trials

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

Completed·AstraZeneca·Phase 1·NCT01458899·18 enrolled

To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects

Completed·AstraZeneca·Phase 1·NCT01175564·48 enrolled

Oral1 trial

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

Completed·AstraZeneca·Phase 1·NCT01145768·72 enrolled

Abuse Potential1 trial

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

Withdrawn·AstraZeneca·Phase 1·NCT01500018

4 more indications

Elderly1 trial

A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers

Completed·AstraZeneca·Phase 1·NCT01392820·48 enrolled

Heart1 trial

Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

Terminated·AstraZeneca·Phase 1·NCT01359618·16 enrolled

Renal Impairment1 trial

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Completed·AstraZeneca·Phase 1·NCT01240967·40 enrolled

Absorption1 trial

A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects

Completed·AstraZeneca·Phase 1·NCT01239771·32 enrolled

Details

Drug Info

Related News